Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
Summarize this article with:
SA Transcripts157.3K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day December 10, 2025 1:00 PM EST Company Participants Susan Hubbard - Executive Vice President of Public Affairs & Investor RelationsMichael Morrissey - CEO, President & DirectorP. Haley - Executive Vice President of CommercialDana Aftab - Executive Vice President of Research & Development Conference Call Participants Toni ChoueiriAnwaar SaeedJennifer Chan Conversation Operator Welcome to the Exelixis virtual event. Please welcome Executive Vice President of Public Affairs and Investor Relations, Susan Hubbard. Susan HubbardExecutive Vice President of Public Affairs & Investor Relations Welcome, everyone, to the Exelixis 2025 R&D Day, building next-generation oncology franchises. We very much appreciate you taking time to join us today. As you can see, we have a very busy agenda and are delighted to be joined during the disease focus areas by 3 guest speakers, Dr. Choueiri, Dr. Saeed and Dr. Chan. But let me just start by saying that during the course of this presentation, we will be making forward-looking statements regarding the future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters and potential market and growth opportunities. Actual events or results could, of course, differ materially. We refer you to the documents we file from time to time with the SEC Commission, which under the heading Risk Factors, identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing on the slides today, including, without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners and the level of cost associated with discovery, product development, business development and commercialization activities.
Recommended For You